Asset profile
VK2809
Small molecule
Evidence outlook · lead readout
VOYAGE (NCT04173065) · NASH - Nonalcoholic Steatohepatitis
The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.
VOYAGE (NCT04173065): This randomized, quadruple-blind, placebo-controlled Phase 2b trial (n=248) in biopsy-confirmed NASH measured its primary result using an imaging-based marker of liver fat (MRI-PDFF) rather than the liver biopsy assessment typically used to support NASH drug approvals. VK2809 produced a significant, dose-dependent reduction in liver fat versus placebo at 12 weeks, up to 51.7% (p<0.0001), a promising early signal that still needs confirmation on the histological outcome collected later in the study.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Also in development:Metabolic Dysfunction-Associated Steatohepatitis
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
38 competitors in this universe: 1 direct rival (same mechanism and indication), 2 same-class, 35 same-indication; 16 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| VK2809: this drug | Phase 2 | Small molecule | Thyroid hormone receptor-beta | ||
| Resmetirom (Rezdiffra) | Approved | Small molecule | Thyroid hormone receptor-beta | ||
| Elunetirom | Phase 2 | Small molecule | Thyroid hormone receptor-beta | ||
| ASC47 | Phase 1 | Small molecule | Thyroid hormone receptor-beta | ||
| Rosuvastatin | Approved | Small molecule | HMG-CoA reductase | ||
| Semaglutide (Wegovy / Ozempic / Rybelsus) | Approved | Peptide | GLP-1 receptor | ||
| ALN-CIDEB | Phase 3 | RNA / oligonucleotide | CIDEB | ||
| Aramchol | Phase 3 | — | Stearoyl-CoA desaturase 1 (SCD1) | ||
| Denifanstat | Phase 3 | Small molecule | Fatty acid synthase (FASN), FASN | ||
| Efimosfermin | Phase 3 | Protein / enzyme therapeutic | FGF21 | ||
| Efimosfermin Alfa | Phase 3 | Protein / enzyme therapeutic | FGF21 receptor | ||
| Lanifibranor | Phase 3 | Small molecule | Peroxisome proliferator-activated receptors (PPARs), PPAR (pan-agonist) | ||
| Lobeglitazone (Duvie) | Phase 3 | Small molecule | PPAR-gamma | ||
| Namodenoson | Phase 3 | — | Adenosine A3 receptor | ||
| ORMD-0801 | Phase 3 | Peptide | Insulin receptor (basal) | ||
| Pemvidutide | Phase 3 | Peptide | GLP-1/glucagon receptor (dual) |
…and 23 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.